Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

Journal of Infection

Volumn 58, Issue 4, 2009, Pages 273-284

  Poulakou, Garyphallia ^a   Kontopidou, Flora V ^a   Paramythiotou, Elisabeth ^a   Kompoti, Maria ^b   Katsiari, Maria ^c   Mainas, Efstratios ^c   Nicolaou, Chara ^c   Yphantis, Dimitrios ^a   Antoniadou, Anastasia ^a   Trikka Graphakos, Eleftheria ^b   Roussou, Zoi ^c   Clouva, Phyllis ^b   Maguina, Nina ^c   Kanellakopoulou, Kyriaki ^a   Armaganidis, Apostolos ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

Antimicrobial resistance; MDR Acinetobacter baumannii; Nosocomial infections; Pan drug resistant Klebsiella pneumoniae

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; CORTICOSTEROID; DOXYCYCLINE; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; EOSINOPHILIA; EPISTAXIS; FEMALE; GENERALIZED EDEMA; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SEPTIC SHOCK; SUPERINFECTION; SURGICAL INFECTION; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHI-SQUARE DISTRIBUTION; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURGICAL WOUND INFECTION;

EID: 63349106277     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.02.009     Document Type: Article

References (34)

1. Fournier P.E., and Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42 (2006) 692-699
2. Diekema D.J., BootsMiller B.J., Vaughn T.E., Woolson R.F., Yankey J.W., Ernst E.J., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
3. Souli M., Kontopidou F.V., Papadomichelakis E., Galani I., Armaganidis A., and Giamarellou H. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 46 (2008) 847-854
4. Hoffman-Roberts H.L., Babcock C.E., and Mitropoulos I.F. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin Investig Drugs 14 (2005) 973-995
5. Sader H.S., Jones R.N., Dowzicky M.J., and Fritsche T.R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52 (2005) 203-208
6. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., and Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl. 5 (2005) S354-S367
7. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G.M., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl. 5 (2005) S341-S353
8. Hoban D.J., Bouchillon S.K., and Dowzicky M.J. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 57 (2007) 423-428
9. Vasilev K., Reshedko G., Orasan R., Sanchez M., Teras J., Babinchak T., et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter species and Klebsiella pneumoniae. J Antimicrob Chemother 62 Suppl. 1 (2008) i29-i40
10. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections. Am J Infect Control 16 (1988) 128-140
11. Kollef M.H. Diagnosis of ventilator-associated pneumonia. N Engl J Med 355 (2006) 2691-2693
12. Anonymous. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
13. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Agnus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31 (2003) 1250-1256
14. Singh N., Rogers P., Atwood C.W., Wagener M.M., and Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162 (2000) 505-511
15. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew P.D., and Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 143 (1991) 1121-1129
16. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., and Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46 (2008) 567-570
17. Crouch Brewer S., Wunderink R.G., Jones C.B., and Leeper Jr. K.V. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109 (1996) 1019-1029
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth international supplement. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
19. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on tigecycline. Clin Microbiol Infect 2006;12:1147-9.
20. Tygacil package insert (2005), Wyeth Pharmaceuticals Inc., Philadelphia, PA
21. McGowan A., and Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests (2005).
22. Lee K., Lim J.B., Yum J.H., Yong D., Chong Y., Kim J.M., et al. bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 46 (2002) 1053-1058
23. Luna C.M., Aruj P., Niederman M.S., Garzón J., Violi D., Prignoni A., et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27 (2006) 158-164
24. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
25. Souli M., Kontopidou F.V., Koratzanis E., Antoniadou A., Giannitsioti E., Evangelopoulou P., et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 50 (2006) 3166-3169
26. Luna C.M., Blanzaco D., Niederman M.S., Matarucco W., Baredes N.C., Desmery P., et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 31 (2003) 676-682
27. Luna C.M., and Niederman M.S. What is the natural history of resolution of nosocomial pneumonia?. Semin Respir Crit Care Med 23 (2002) 471-479
28. Schafer J.J., Goff D.A., Stevenson K.B., and Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteraemia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27 (2007) 980-987
29. Swoboda S., Ober M., Hainer C., Lichtenstern C., Seiler C., Wendt C., et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61 (2008) 729-733
30. Gallagher J.C., and Rouse H.M. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 42 (2008) 1188-1194
31. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., and Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62 (2008) 45-55
32. Evagelopoulou P., Myrianthefs P., Markogiannakis A., Baltopoulos G., and Tsakris A. Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline. Clin Infect Dis 46 (2008) 1932-1933
33. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59 (2007) 128-131
34. Kontopidou F.V., Poulakou G., Antoniadou A., Papadomichelakis E.D., Galani I., Armaganidis A., et al. Emerging colimycin resistance in the ICU: what does the future hold?. 47th interscience conference on antimicrobial agents and chemotherapy (2007) [K-448]